Phio Pharmaceuticals Corp (PHIO)

$1.09 +0.01 (0.93%)
Market Cap 11.73M
Revenue (ttm) 0.00
Net Income (ttm) -7.15M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 202,700
Avg Vol 410,538
Day's Range N/A - N/A
Shares Out 10.76M
Stochastic %K 38%
Beta 0.89
Analysts Sell
Price Target $14.00

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology
Sector: Healthcare
Phone: 508 767 3861
Address:
11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States
WildernessRefuge
WildernessRefuge Jan. 26 at 3:31 AM
$PHIO Here are some notes I typed out while listening to the Sidoti January Conference for PHIO. Typos and misspellings are included: Market hasn't captured the full value of what Intasyl is in the share price. Seeking out license partners, outside of US marketplace Greater or as good response as MABs FDA briefing packing with scrubbed data with proposal of design of study for next phase a phase 2b rolling over into a phase 3 pivotal safety is compelling, results/efficacy guide statistical design putting package together and getting FDA response will take time through the end of Q2 marmoset tox study is going on now- marmosets have a similar PD-1 gene, outcome is in Q4. CGMP is underway needs to be meet standards for registration material with FDA, will take 7 months prove active pharmaceutical component 894 has all IND enabling studies completed middle of year feedback from FDA, need cash, and don't want much distraction from 762
1 · Reply
JKtech
JKtech Jan. 25 at 2:36 PM
Small-cap Oncology watch for the DealFlow Discovery Conference in Atlantic City (Jan 28-29). ​Looking for catalysts @ #DealFlow2026. Key management presentations and 1-on-1 meetings to watch: ​ $KAPA (Kairos Pharma): Focused on overcoming drug resistance. Chief Scientific Officer Neil Bhowmick is presenting their structural biology approach to reversing immune suppression in cancer. $DRTS (Alpha Tau): Utilizing Alpha DaRT technology for solid tumors. Momentum building from recent pancreatic trial updates and their targeted alpha-radiation platform. ​$LIXT (Lixte Biotech): Advancing LB-100 as a first-in-class PP2A inhibitor. CEO Geordan Pursglove is holding 1-on-1s to discuss activation lethality in combination therapies. ​$FBLG (FibroBiologics): CEO Pete O’Heeron presents Jan 29 at 11:30 AM. Unique play using fibroblast-derived materials to modify the tumor microenvironment. ​ $PHIO (Phio Pharma): Leveraging the INTASYL pro-RNAi platform to silence genes help tumors evade the immune system.
2 · Reply
LongAllDay
LongAllDay Jan. 23 at 7:14 PM
$PHIO They must be curing insomnia cause this thing is a SNORE FEST
0 · Reply
CoffeeBender
CoffeeBender Jan. 23 at 6:18 PM
$PHIO around
0 · Reply
Stonkey
Stonkey Jan. 23 at 3:24 PM
$PHIO dumped
0 · Reply
Stonkey
Stonkey Jan. 23 at 3:23 PM
$PHIO don’t sleep on it
0 · Reply
Stonkey
Stonkey Jan. 23 at 3:23 PM
$PHIO
0 · Reply
zannnn
zannnn Jan. 23 at 12:08 PM
$PHIO
0 · Reply
nepepe
nepepe Jan. 23 at 12:23 AM
$PHIO don’t sleep on it
0 · Reply
nepepe
nepepe Jan. 23 at 12:23 AM
$PHIO loaded up
0 · Reply
Latest News on PHIO
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 20, 2026, 9:30 AM EST - 5 days ago

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Jan 15, 2026, 8:45 AM EST - 10 days ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Dec 23, 2025, 8:45 AM EST - 4 weeks ago

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 25, 2025, 11:30 AM EST - 2 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 17, 2025, 8:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:15 PM EST - 2 months ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 10:30 AM EST - 2 months ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 7, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 1:40 PM EST - 2 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Nov 3, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 31, 2025, 10:15 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Oct 21, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 18, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 4:15 PM EDT - 5 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 3:04 PM EDT - 6 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 12:36 PM EDT - 6 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jul 25, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 25, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 24, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Jun 6, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:15 PM EDT - 9 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 7, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 9, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Apr 3, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025, 4:00 PM EDT - 10 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 10, 2025, 7:45 AM EDT - 11 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Mar 5, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Feb 20, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 12:45 PM EST - 1 year ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

WildernessRefuge
WildernessRefuge Jan. 26 at 3:31 AM
$PHIO Here are some notes I typed out while listening to the Sidoti January Conference for PHIO. Typos and misspellings are included: Market hasn't captured the full value of what Intasyl is in the share price. Seeking out license partners, outside of US marketplace Greater or as good response as MABs FDA briefing packing with scrubbed data with proposal of design of study for next phase a phase 2b rolling over into a phase 3 pivotal safety is compelling, results/efficacy guide statistical design putting package together and getting FDA response will take time through the end of Q2 marmoset tox study is going on now- marmosets have a similar PD-1 gene, outcome is in Q4. CGMP is underway needs to be meet standards for registration material with FDA, will take 7 months prove active pharmaceutical component 894 has all IND enabling studies completed middle of year feedback from FDA, need cash, and don't want much distraction from 762
1 · Reply
JKtech
JKtech Jan. 25 at 2:36 PM
Small-cap Oncology watch for the DealFlow Discovery Conference in Atlantic City (Jan 28-29). ​Looking for catalysts @ #DealFlow2026. Key management presentations and 1-on-1 meetings to watch: ​ $KAPA (Kairos Pharma): Focused on overcoming drug resistance. Chief Scientific Officer Neil Bhowmick is presenting their structural biology approach to reversing immune suppression in cancer. $DRTS (Alpha Tau): Utilizing Alpha DaRT technology for solid tumors. Momentum building from recent pancreatic trial updates and their targeted alpha-radiation platform. ​$LIXT (Lixte Biotech): Advancing LB-100 as a first-in-class PP2A inhibitor. CEO Geordan Pursglove is holding 1-on-1s to discuss activation lethality in combination therapies. ​$FBLG (FibroBiologics): CEO Pete O’Heeron presents Jan 29 at 11:30 AM. Unique play using fibroblast-derived materials to modify the tumor microenvironment. ​ $PHIO (Phio Pharma): Leveraging the INTASYL pro-RNAi platform to silence genes help tumors evade the immune system.
2 · Reply
LongAllDay
LongAllDay Jan. 23 at 7:14 PM
$PHIO They must be curing insomnia cause this thing is a SNORE FEST
0 · Reply
CoffeeBender
CoffeeBender Jan. 23 at 6:18 PM
$PHIO around
0 · Reply
Stonkey
Stonkey Jan. 23 at 3:24 PM
$PHIO dumped
0 · Reply
Stonkey
Stonkey Jan. 23 at 3:23 PM
$PHIO don’t sleep on it
0 · Reply
Stonkey
Stonkey Jan. 23 at 3:23 PM
$PHIO
0 · Reply
zannnn
zannnn Jan. 23 at 12:08 PM
$PHIO
0 · Reply
nepepe
nepepe Jan. 23 at 12:23 AM
$PHIO don’t sleep on it
0 · Reply
nepepe
nepepe Jan. 23 at 12:23 AM
$PHIO loaded up
0 · Reply
DosGatos
DosGatos Jan. 22 at 11:03 PM
$PHIO
0 · Reply
AJWW316
AJWW316 Jan. 22 at 9:58 PM
$PHIO echo this, did anyone listen in ? Had a little trickle up today so it can’t of been anything negative.
0 · Reply
dln101
dln101 Jan. 22 at 8:46 PM
$PHIO this low float bio itching for $SXTP $IOBT moves 🤔💪🔥🚀
0 · Reply
Sidoti
Sidoti Jan. 22 at 8:03 PM
Phio Pharmaceuticals Corp. ($PHIO) Management Team presented today at the Sidoti Micro-Cap Virtual Conference. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_AZ-3eOfHQZaq86JVCZZUuQ
0 · Reply
gronekty7
gronekty7 Jan. 22 at 7:24 PM
$PHIO anything good said at the conference?
0 · Reply
DERDER
DERDER Jan. 22 at 7:23 PM
$PHIO
0 · Reply
AJWW316
AJWW316 Jan. 22 at 7:23 PM
$PHIO
0 · Reply
CertaTrader
CertaTrader Jan. 22 at 5:24 PM
$PHIO
0 · Reply
Smith_84
Smith_84 Jan. 22 at 1:23 PM
$PHIO
0 · Reply
zannnn
zannnn Jan. 22 at 11:46 AM
$PHIO
0 · Reply
WildernessRefuge
WildernessRefuge Jan. 21 at 5:47 PM
$PHIO PHIO has a webinar on Sidoti tomorrow afternoon (January 22, 2026). I have always found CEO Bitterman to be upfront and honest. He has always detailed the capital raise needs of the company on Sidoti Road Shows in the past, and I would expect an update from Bitterman about possible dilution (remember there is a 50% overhang of warrants here already). Here is a link to sign up:https://sidoti.zoom.us/webinar/register/WN_AZ-3eOfHQZaq86JVCZZUuQ#/registration I do not work for Sidoti, or PHIO. I have been following PHIO for about a year and have bought and sold stock over this past year, I currently own no shares.
0 · Reply
DosGatos
DosGatos Jan. 21 at 3:35 PM
$PHIO Tammy is still holding with a target of 0.70 that is correct!
0 · Reply